ZYNTEGLO (betibeglogene autotemcel) PRIOR AUTHORIZATION FORM
Customize your policy alerts
Sign up for all Geisinger Health Plan policy alerts
Know when Geisinger Health Plan releases new policies or updates existing guidance.
Monitor payer policy activity
This document is a prior authorization form and instructions for requesting coverage of Zynteglo for Geisinger Health Plan beneficiaries; it affects prescribers, billing providers, and plan beneficiaries seeking authorization for Zynteglo.
No material clinical or coverage changes in this revision.
Authorization Criteria for Zynteglo
Authorization criteria
Covered when ALL of the following are met:
ALL of the following
- Prescriber confirms beneficiary has NOT received prior gene therapy.
Form includes checkbox to confirm beneficiary has NOT received prior gene therapy; submit supporting documentation (e.g., chart/clinic notes).
- Prescriber confirms beneficiary has NOT received a prior allogeneic hematopoietic stem cell transplant (HSCT).
Form includes checkbox to confirm no prior allogeneic HSCT; submit supporting documentation.
- Genetic testing confirming the diagnosis of β‑thalassemia is provided.
Form includes checkbox for genetic testing; submit the genetic test results.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.